Literature DB >> 33243776

Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer.

Gretchen Glaser1, Giorgia Dinoi2, Francesco Multinu3, Kathleen Yost4, Mariam Al Hilli5, Alyssa Larish6, Amanika Kumar7, Michaela McGree8, Amy L Weaver9, Andrea Cheville10, Sean Dowdy11, Andrea Mariani12.   

Abstract

OBJECTIVE: Endometrial cancer surgical staging includes lymph node assessment which can lead to lower extremity lymphedema. The aim of this study was to estimate prevalence after sentinel lymph node biopsy versus lymphadenectomy.
METHODS: Consecutive patients who underwent minimally invasive surgery at the Mayo Clinic, Rochester, Minnesota, USA, between January 2009 and June 2016 for newly diagnosed endometrial cancer were mailed our validated 13 item lower extremity lymphedema screening questionnaire. We also ascertained via questionnaire whether the patient was ever diagnosed with lower extremity lymphedema.
RESULTS: Among 378 patients included in the analysis, 127 (33.5%) had sentinel lymph node biopsy with or without side specific lymphadenectomy (sentinel lymph node cohort) and 251 (66.4%) underwent bilateral lymphadenectomy prior to sentinel lymph node biopsy implementation at our institution or as 'backup' after sentinel lymph node mapping (lymphadenectomy cohort). The prevalence of lower extremity lymphedema was 41.5% (157/378), with 69 patients (18.3%) self-reporting a lower extremity lymphedema diagnosis after their endometrial cancer surgery at a median of 54.3 months (interquartile range 31.2-70.1 months), and an additional 88 patients (23.3%) identified by the screening questionnaire. The prevalence of lower extremity lymphedema was significantly higher in the lymphadenectomy cohort compared with the sentinel lymph node group (49.4% (124/251) vs 26.0% (33/127); p<0.001). When the cohorts were restricted to patients surgically managed after the introduction of sentinel lymph node, the prevalence of lower extremity lymphedema was still significantly higher in the lymphadenectomy cohort compared with the sentinel lymph node cohort (39.0% (41/105) vs 26.0% (33/127); p=0.03). In a multivariable analysis adjusted for body mass index, receipt of adjuvant external beam radiation, diabetes, congestive heart failure, and International Federation of Gynecology and Obstetrics grade, the adjusted odds ratio for the association between type of nodal sampling (lymphadenectomy cohort vs sentinel lymph node cohort) and lower extremity lymphedema was 2.75 (95% confidence interval 1.69 to 4.47, p<0.001).
CONCLUSIONS: Sentinel lymph node biopsy was associated with a decreased risk of post-treatment lymphedema compared with lymphadenectomy in patients who underwent surgical staging for endometrial carcinoma. © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  SLN and lympadenectomy; endometrial neoplasms; lymphatic system

Mesh:

Year:  2020        PMID: 33243776     DOI: 10.1136/ijgc-2020-001924

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

Review 1.  Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer.

Authors:  Lina Salman; Maria C Cusimano; Zibi Marchocki; Sarah E Ferguson
Journal:  Curr Oncol       Date:  2022-02-14       Impact factor: 3.677

2.  Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer.

Authors:  Alison A Garrett; Alyssa Wield; Brigid Mumford; Isabel Janmey; Li Wang; Philip Grosse; Emily MacArthur; Ronald Buckanovich; Madeleine Courtney-Brooks; Paniti Sukumvanich; Jessica Berger; Alexander B Olawaiye; Haider Mahdi; Michelle Boisen; Robert P Edwards; Lan Coffman; Sarah E Taylor; Jamie Lesnock
Journal:  Gynecol Oncol Rep       Date:  2022-10-07

Review 3.  Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review.

Authors:  Lirong Zhai; Xiwen Zhang; Manhua Cui; Jianliu Wang
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.